Apr 20,2022

Latest DiGA Approval Makes HelloBetter Global Leader in Prescription Digital Therapeutics (PDTx)

HelloBetter Panic has recently secured approval as HelloBetter’s fifth DiGA (Digital Health Application), making the Panic programme becoming available for prescription in Germany. HelloBetter Panic offers straightforward and wait-free access to individualised psychological help for people suffering from panic disorders or agoraphobia with panic disorder.

PRODUCT

#reimbursement

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
May 01,2022

Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune and DreAMLand

Blue Note Therapeutics and Bixink Therapeutics, a bio-subsidiary of KPS, today announced that the companies have entered into an exclusive licensing agreement for the commercialization of Blue Note’s prescription digital therapeutics (PDTs) in South Korea. The agreement includes attune™ and DreAMLand™, Blue Note’s lead PDTs designed to support the mental well-being of patients living with cancer.

COLLABORATION PARTNERSHIP

#institution

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 05,2022

How DeepWell is developing video games as tools for treating medical conditions

More than just a game, it’s a futuristic component of mental health therapy as envisioned by DeepWell Digital Therapeutics, a new entry in the growing field of treating and managing medical conditions with software. Seattle-based company launched in March with the goal of creating best-in-class gameplay that can entertain while simultaneously delivering, enhancing and accelerating treatment for an array of globally pervasive health conditions.

View Analyst & Ambassador Comments
Go to original news
May 31,2022

OncoHealth and Blue Note Therapeutics Partner to Provide a Digital Therapeutic for Treating Cancer-Related Anxiety and Depression Symptoms

Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, and OncoHealth, a leading digital health company dedicated to oncology, have partnered to support patients coping with cancer by delivering oncology-specific mental health care. Through OncoHealth's telehealth platform, Iris™, licensed healthcare professionals will now provide Blue Note's attune™ to patients living with cancer. Blue Note developed attune as an “on-demand” self-directed tool for patients with cancer. 

COLLABORATION PARTNERSHIP

#institution

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Attune Ensemble™ OTC, a First of its Kind Cancer Well-Being App, is Now Available for Free to Spanish-Speaking Patients

Blue Note Therapeutics today announced plans to provide Spanish-speaking patients with immediate access to a new cancer-specific wellness app, attune ensemble™ OTC. The wellness app is a first-of-its-kind digital therapy designed to help patients cope with the emotional symptoms of cancer, such as stress. Providing attune ensemble OTC in Spanish supports Blue Note’s goal of providing all patients with access to cancer-specific support to ease the burdens of cancer and improve outcomes.

PRODUCT

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

ieso Announces Results Showing Novel Form of Online Cognitive Behavioral Therapy Improves Patient Outcomes in Type 2 Diabetes

ieso, a data-driven AI healthcare company pioneering next-generation digital therapeutics in mental health, announced today study results showing that integrated approaches for mental healthcare in diabetes patients improved mental health outcomes, patient engagement with self-management of diabetes, diabetes distress, and quality of life. This study, conducted with support from Roche Diabetes Care Limited, enrolled 102 patients and evaluated the effect of a novel online CBT tailored for patients with type 2 diabetes.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jun 10,2022

Anthem Partners with Happify to Launch a New Digital Maternal Health Platform

Anthem and Happify Health are teaming up to help bridge the gap between the unique physical and mental health concerns women face. Anthem is collaborating with Happify Health to develop a Sequence focused on maternal health. Eligible members of Anthem’s affiliated health plans in select markets will have access to Happify Health’s online pregnancy community, where they can connect with mental health experts, obstetrics, and gynecology experts, dietitians, and other healthcare professionals, ask questions, and discuss their physical challenges, and develop meaningful connections with others dealing with similar health issues. Eligible members will also have access to Happify Health’s evidence-based digital therapeutics, including a new non-prescription digital therapeutic addressing mental health needs during pregnancy.

COLLABORATION PARTNERSHIP

#insurance

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 21,2022

DarioHealth Announces New Contract with a National Employer

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its digital behavioral health solution for a leading provider of integrated technology solutions for financial professionals. The new account is expected to launch in the third quarter of 2022.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 01,2022

Your next therapist could be a chatbot app

Today, anyone with a smartphone can access conversational agent phone apps, or chatbots, meant to help users cope with the anxieties of daily life. These AI language-processing systems can imitate human discussion via text — in this case, by simulating conversations with a therapist. (For now, though, they aren’t usually branded as therapy.) One version, Woebot, was launched by clinical research psychologist Alison Darcy and other Stanford University scientists in 2017. Darcy says she looked into Woebot to tackle disparities in access to mental health care, though she acknowledges it’s only part of the solution.

PRODUCT

#chatbot

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 13,2022

Orexo’s digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today it has been granted a Veteran Affairs Federal Supply Schedule (VA FFS) contract for deprexis®, an evidence-based digital therapy for the treatment of symptoms of depression. As of late July 2022, deprexis® will be reimbursed by the federal government and made available to federal healthcare providers, including Veterans Affairs (VA), Indian Health Service (IHS) and Department of Defense (DOD). The contract will expire in 2032.

PRODUCT

#cbt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH